Hogan Lovells is representing LabCorp, a leading health care diagnostics company, on its offering of US$1.2 billion in senior notes.
The offering consists of two tranches: US$600 million aggregate principal amount of 3.250% Senior Notes due 2024 and US$600 million aggregate principal amount of 3.600% Senior Notes due 2027. The closing of the offering is expected to occur on August 22, 2017, subject to the satisfaction of customary closing conditions.
Corporate partners Michael Silver and William Intner and associates Ben Massey and Lauren Heller led the team on the offering. Other key members of the Hogan Lovells team include Eve Howard, Tifarah Allen and Scott Lilienthal.
Hogan Lovells has advised LabCorp for more than a decade on many of its most significant securities offerings and strategic transactions including acquisitions of: Chiltern, Covance, Genzyme Genetics, Pathology Associates Medical Laboratories (PAML), Mount Sinai Health System Clinical Outreach Laboratories, Monogram Biosciences, Medtox, Liposcience and Sequenom.
